168 related articles for article (PubMed ID: 30640697)
1. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.
Taylor SE; Petschauer JS; Donovan H; Schorzman A; Razo J; Zamboni WC; Edwards RP; Zorn KK
Int J Gynecol Cancer; 2019 Jan; 29(1):147-152. PubMed ID: 30640697
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
Taylor SE; Li R; Petschauer JS; Donovan H; O'Neal S; Keeler AW; Zamboni WC; Edwards RP; Zorn KK
Gynecol Oncol; 2015 Sep; 138(3):548-53. PubMed ID: 26111788
[TBL] [Abstract][Full Text] [Related]
3. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
[TBL] [Abstract][Full Text] [Related]
4. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
5. Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Becker DA; Leath CA; Walters-Haygood CL; Smith BQ; Bevis KS
Am J Clin Oncol; 2019 Jan; 42(1):12-16. PubMed ID: 29782365
[TBL] [Abstract][Full Text] [Related]
6. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
[TBL] [Abstract][Full Text] [Related]
8. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Herzog TJ; Monk BJ; Rose PG; Braly P; Hines JF; Bell MC; Wenham RM; Secord AA; Roman LD; Einstein MH; Drake RD; Childs BH
Gynecol Oncol; 2014 Mar; 132(3):517-25. PubMed ID: 24476788
[TBL] [Abstract][Full Text] [Related]
10. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Dizon DS; Sill MW; Gould N; Rubin SC; Yamada SD; Debernardo RL; Mannel RS; Eisenhauer EL; Duska LR; Fracasso PM
Gynecol Oncol; 2011 Nov; 123(2):182-6. PubMed ID: 21820161
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
12. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Chambers SK; Chow HH; Janicek MF; Cragun JM; Hatch KD; Cui H; Laughren C; Clouser MC; Cohen JL; Wright HM; Abu Shahin N; Alberts DS
Clin Cancer Res; 2012 May; 18(9):2668-78. PubMed ID: 22421191
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
17. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
18. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
Cohen S; Schwartz M; Dottino P; Beddoe AM
J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]